Company Filing History:
Years Active: 2021-2024
Title: Innovations of Frank Espin: Advancing Alpha-Synuclein Detection
Introduction
Frank Espin, an accomplished inventor based in Oceanside, California, has made significant contributions to the field of biomedical research. With two patents to his name, his work centers on critical methods for detecting misfolded proteins, which play a vital role in various neurodegenerative diseases.
Latest Patents
Frank's latest invention focuses on "Alpha-synuclein detection using beads." This innovative method enables the determination of the presence of soluble, misfolded α-synuclein protein in a biological sample. The procedure involves contacting the biological sample with a pre-incubation mixture that includes a monomeric α-synuclein protein, a buffer composition, a salt, and an indicator. Following this, an incubation cycle is performed with the mixture using either silicon nitride beads or borosilicate glass beads, measuring from about 1 mm to about 5 mm in diameter. The method culminates in a determination of whether a detectable amount of misfolded α-synuclein aggregate is present in the sample, crucial for diagnosing and understanding conditions like Parkinson's disease.
Career Highlights
Currently, Frank works at Amprion, Inc., a company specializing in protein misfolding and neurodegenerative diseases. His expertise and dedication to advancing medical research are evident in his innovative approaches to complex biological challenges.
Collaborations
In his professional journey, Frank collaborates with notable colleagues such as Luis Concha and Carly Farris. Together, they contribute to Amprion's goal of improving diagnostics and treatment options for neurodegenerative diseases through innovative research and technology.
Conclusion
Frank Espin exemplifies the role of an innovative inventor in the biomedical research field. His contributions to the detection of misfolded α-synuclein proteins provide essential advancements for understanding and potentially treating severe neurological conditions. As he continues his work at Amprion, Inc., the impact of his inventions and collaboration with skilled professionals like Concha and Farris is poised to make significant strides in medical science.